Literature DB >> 32030300

The clinical significance of ground glass opacities in lung adenocarcinoma in the era of UICC-TNM classification ver.8.

Masayoshi Inoue1, Masanori Shimomura1.   

Abstract

Entities:  

Year:  2019        PMID： 32030300      PMCID： PMC6988044          DOI： 10.21037/jtd.2019.12.58

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

Review 1.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2016-04-21       Impact factor: 15.609

2.  Consolidation-to-tumor ratio and tumor disappearance ratio are not independent prognostic factors for the patients with resected lung adenocarcinomas.

Authors:  Hyungjin Kim; Jin Mo Goo; Young Tae Kim; Chang Min Park
Journal:  Lung Cancer       Date:  2019-09-17       Impact factor: 5.705

3.  Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2 cm.

Authors:  Jun-Ichi Nitadori; Adam J Bograd; Eduardo A Morales; Nabil P Rizk; Mark P S Dunphy; Camelia S Sima; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2013-08-17       Impact factor: 5.344

4.  Predictive factors of pathologically proven noninvasive tumor characteristics in T1aN0M0 peripheral non-small cell lung cancer.

Authors:  Yoshihisa Shimada; Junji Yoshida; Tomoyuki Hishida; Mitsuyo Nishimura; Genichiro Ishii; Kanji Nagai
Journal:  Chest       Date:  2011-08-18       Impact factor: 9.410

5.  Prognostic Impact of the Findings on Thin-Section Computed Tomography in Patients with Subcentimeter Non-Small Cell Lung Cancer.

Authors:  Aritoshi Hattori; Takeshi Matsunaga; Takuo Hayashi; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  J Thorac Oncol       Date:  2017-02-28       Impact factor: 15.609

6.  Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.

Authors:  Yuichiro Tsurugai; Takuyo Kozuka; Naoki Ishizuka; Masahiko Oguchi
Journal:  Lung Cancer       Date:  2015-12-17       Impact factor: 5.705

7.  Prognostic value of tumor disappearance rate on computed tomography in advanced-stage lung adenocarcinoma.

Authors:  Norihiro Haraguchi; Hiroaki Satoh; Norihiro Kikuchi; Katsunori Kagohashi; Hiroichi Ishikawa; Morio Ohtsuka
Journal:  Clin Lung Cancer       Date:  2007-03       Impact factor: 4.785

8.  Prognostic impact of nomogram based on whole tumour size, tumour disappearance ratio on CT and SUVmax on PET in lung adenocarcinoma.

Authors:  So Hee Song; Joong Hyun Ahn; Ho Yun Lee; Geewon Lee; Joon Young Choi; Jun Kang; Eun Young Kim; Joungho Han; O Jung Kwon; Kyung Soo Lee; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim
Journal:  Eur Radiol       Date:  2015-10-11       Impact factor: 5.315

9.  The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma.

Authors:  Yasuhisa Ohde; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Kenro Takahashi; Kenji Suzuki; Kazuya Takamochi; Tomoyuki Yokose; Yutaka Nishiwaki
Journal:  Lung Cancer       Date:  2003-12       Impact factor: 5.705

10.  Volume-Based Consolidation-to-Tumor Ratio Is a Useful Predictor for Postoperative Upstaging in Stage I and II Lung Adenocarcinomas.

Authors:  Masanori Shimomura; Masashi Iwasaki; Shunta Ishihara; Masayoshi Inoue
Journal:  Thorac Cardiovasc Surg       Date:  2019-08-08       Impact factor: 1.827
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.